var data={"title":"Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/contributors\" class=\"contributor contributor_credentials\">J Kevin Baird, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/contributors\" class=\"contributor contributor_credentials\">Ric Price, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/contributors\" class=\"contributor contributor_credentials\">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Non-falciparum malaria refers to malaria infection due to <em>Plasmodium</em> species other than <em>P. falciparum</em>; these include <em>P. vivax</em>, <em>P. ovale</em>, <em>P. malariae</em>, and <em>P. knowlesi</em> (<a href=\"image.htm?imageKey=ID%2F53291\" class=\"graphic graphic_table graphicRef53291 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Worldwide, the greatest mortality due to malaria is associated with <em>P. falciparum</em> infection. Infections caused by<em> P. knowlesi</em> and <em>P. vivax</em> are also associated with significant risk of morbidity and mortality [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/2-4\" class=\"abstract_t\">2-4</a>]; patients with uncomplicated malaria due to these species are vulnerable to deterioration even after initiation of treatment, and <em>P. vivax</em> infection may be complicated by recurrent infection and associated anemia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/5\" class=\"abstract_t\">5</a>]. Rarely, severe illness and death occur in the setting of infection with <em>P. malariae</em> or <em>P. ovale </em>[<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/6-8\" class=\"abstract_t\">6-8</a>].</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of non-falciparum malaria due to <em>P. vivax, P. ovale,</em> and <em>P. malariae</em> in nonpregnant adults and children will be reviewed here. Issues related to non-falciparum malaria in pregnant women are discussed separately, as are issues related to malaria caused by <em>P. falciparum</em> and <em>P. knowlesi</em>. (See <a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Treatment of uncomplicated falciparum malaria in nonpregnant adults and children&quot;</a> and <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women#H4\" class=\"medical medical_review\">&quot;Prevention and treatment of malaria in pregnant women&quot;, section on 'Non-falciparum malaria'</a> and <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-knowlesi\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium knowlesi&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The epidemiology of non-falciparum malaria is variable depending on the species, as described in the following sections. Issues related to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> are most significant in the setting of <em>P. vivax</em> infection, as discussed below.</p><p class=\"headingAnchor\" id=\"H2639591244\"><span class=\"h2\">Non-falciparum malaria species</span></p><p class=\"headingAnchor\" id=\"H1692802959\"><span class=\"h3\">Plasmodium vivax</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Of the non-falciparum species, <em>P. vivax</em> is the most important; approximately one-third of the world's population is at risk for infection caused by this species [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>]. <em>P. vivax</em> accounts for approximately 9 percent of malaria cases worldwide and is the dominant malaria species outside Africa [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/9,10\" class=\"abstract_t\">9,10</a>]. In most areas where <em>P. vivax</em> is prevalent, malaria transmission rates are low (the island of New Guinea is an exception); therefore, affected populations achieve little immunity, and people of all ages are at risk.</p><p>Endemic vivax malaria occurs throughout most of the tropics, including Africa, Asia, the South Pacific, and Central and South America. It may occur at any latitude capable of supporting anopheline mosquitoes (even for brief periods) including temperate latitudes on the Korean peninsula, China, Russia, and countries in northwestern Asia such as Turkey, Iraq, Iran, Afghanistan, and Tajikistan. Among travelers diagnosed with <em>P. vivax</em> in North American or European clinics, those visiting friends and relatives in India and Pakistan are at greatest risk [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/11\" class=\"abstract_t\">11</a>]. Local outbreaks of <em>P. vivax</em> infection have occurred as a result of transmission of infection from migrant workers to anopheline mosquitoes in Greece and the United States [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>The life cycles of <em>P. vivax</em> and<em> P. ovale</em> include hypnozoites, which are dormant stages in the liver that can reactivate weeks, months, or years after the initial infection, causing relapse [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/14\" class=\"abstract_t\">14</a>]. One study in Papua New Guinea suggested that most episodes of vivax malaria infection reflect relapse from the hypnozoite reservoir rather than new infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/15\" class=\"abstract_t\">15</a>]. Relapsed infections are also likely to be an important source of ongoing transmission [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/16-18\" class=\"abstract_t\">16-18</a>]. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> below and <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p>The absence of Duffy factor on the surface of red blood cells among most Africans was previously believed to protect most West and Central African populations from malaria due to <em>P. vivax</em>. However, more subsequent evidence suggests that transmission of <em>P. vivax</em> is possible even among Duffy antigen-negative populations in East and West Africa, the Amazon River basin, and Madagascar [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/19-25\" class=\"abstract_t\">19-25</a>]. (See <a href=\"topic.htm?path=protection-against-malaria-by-abnormalities-in-red-cell-surface-antigens-and-cytoskeletal-proteins\" class=\"medical medical_review\">&quot;Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins&quot;</a>.)</p><p>The mortality associated with severe <em>P. vivax</em> infection varies between reports. In endemic settings, the mortality rate among patients with severe disease ranges from 5 to 25 percent [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/26-31\" class=\"abstract_t\">26-31</a>]. Young infants and pregnant women are at particular risk [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Nonimmune travelers are at risk for life-threatening illness [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/34,35\" class=\"abstract_t\">34,35</a>], although mortality in nonendemic resource-rich settings is generally low [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H2392538086\"><span class=\"h3\">Plasmodium ovale</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. ovale</em> malaria is endemic to tropical western Africa. It is also endemic in Southeast Asia and Oceania but is relatively rare in these areas [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/36\" class=\"abstract_t\">36</a>]. One survey in Indonesia including more than 15,000 blood smears noted 34 individuals with <em>P. ovale </em>infection; the frequency of <em>P. ovale</em> relative to <em>P. falciparum</em> and <em>P. vivax</em> was &lt;1:1000 [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/37\" class=\"abstract_t\">37</a>]. <em>P. ovale</em> may be composed of two coexisting species: <em>Plasmodium ovale curtisi</em> and <em>Plasmodium ovale wallikeri</em> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/38\" class=\"abstract_t\">38</a>].</p><p>The life cycles of <em>P. ovale</em> and <em>P. vivax </em>include hypnozoites, which are dormant stages in the liver that can reactivate weeks, months, or years after the initial infection, causing relapse [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> below and <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p class=\"headingAnchor\" id=\"H938178689\"><span class=\"h3\">Plasmodium malariae</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. malariae</em> infection occurs in Africa, Southeast Asia, Oceania, and South America. The prevalence is relatively low; in general, <em>P. malariae</em> occurs in areas of stable malaria transmission [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/39,40\" class=\"abstract_t\">39,40</a>]. <em>P. malariae</em> is unique in its ability to cause attacks even decades after exposure; the mechanism of persistence is unknown [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/41\" class=\"abstract_t\">41</a>].</p><p><em>P. knowlesi</em> may be misdiagnosed as <em>P. malariae</em> microscopically. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-knowlesi#H1623954686\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium knowlesi&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H3096494374\"><span class=\"h2\">Chloroquine resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> resistance is most significant in the setting of <em>P. vivax</em> infection; it is defined as persistent <em>P. vivax</em> parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy. Additional information regarding malaria endemic countries with evidence of reduced chloroquine efficacy may be found <a href=\"http://www.wwarn.org/vivax/surveyor/&amp;token=G8TYgnOok8yA9OY7AVB4oJqRCYN3Gul/dqY0wMMOSTeV61yjExomaI+VSxgddN1l&amp;TOPIC_ID=5706\" target=\"_blank\" class=\"external\">online</a>.</p><p>Chloroquine-resistant <em>P. vivax</em> (CRPV) has been recognized since the early 1990s [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/42-44\" class=\"abstract_t\">42-44</a>]. One report noted the presence of <em>P. vivax</em> with reduced <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> susceptibility in almost all vivax-endemic countries except India and Afghanistan [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/45\" class=\"abstract_t\">45</a>]. Resistance is particularly severe on the island of New Guinea (including Papua New Guinea and Papua, Indonesia), where over 60 percent of patients fail treatment with chloroquine and a high proportion require hospitalization [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/46,47\" class=\"abstract_t\">46,47</a>]. There is also evidence of CRPV to a lesser degree in most <em>P. vivax</em>&ndash;endemic countries [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"#H19\" class=\"local\">'Chloroquine-resistant infection'</a> below.)</p><p>There are some reports of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> failure in patients with infection due to <em>P. malariae</em>; these may reflect inadequate drug absorption rather than drug resistance [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/48\" class=\"abstract_t\">48</a>]. Prolonged clearance time for <em>P. malariae</em> parasitemia (&ge;3 days) has been described in some cases and likely reflects the life cycle duration (72 hours) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/49\" class=\"abstract_t\">49</a>]. A subsequent study comparing chloroquine with artesunate-mefloquine also achieved 100 percent cure, although parasite clearance was faster with the artesunate-containing regimen [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some clinical manifestations are common to all species of non-falciparum malaria (see <a href=\"#H1913660804\" class=\"local\">'Overview'</a> below), and some clinical manifestations are associated with particular species (see <a href=\"#H600000324\" class=\"local\">'By species'</a> below).</p><p>Relapse can occur in association with <em>P. vivax</em> or <em>P. ovale </em>infection (see <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> below), and hyperreactive malarial splenomegaly (HMS) is a complication of chronic malaria (see <a href=\"#H13\" class=\"local\">'Hyperreactive splenomegaly'</a> below).</p><p class=\"headingAnchor\" id=\"H1913660804\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incubation period of non-falciparum malaria is 9 to 14 days. Nonimmune patients usually develop a febrile illness; semi-immune individuals may present with fever, be asymptomatic, or present with illness in the absence of fever. Most nonimmune patients have daily fever. In semi-immune individuals, the interval between febrile episodes may reflect the duration of the reproductive cycle of the infecting species (<em>P. falciparum, P. vivax,</em> and <em>P. ovale</em>: 48 hours [tertian]; <em>P. malariae</em>: 72 hours [quartan]) (<a href=\"image.htm?imageKey=ID%2F70176\" class=\"graphic graphic_figure graphicRef70176 \">figure 1</a>). </p><p>Clinical manifestations of uncomplicated malaria are nonspecific and may include fever, chills, diaphoresis, headache, fatigue, malaise, myalgia, arthralgia, tachycardia, tachypnea, cough, anorexia, nausea, vomiting, abdominal pain, and diarrhea. Physical findings may include jaundice, splenomegaly, <span class=\"nowrap\">and/or</span> hepatomegaly. Febrile seizures may occur in the setting of uncomplicated malaria.</p><p>Clinical manifestations of severe malaria may occur with any malaria species, in the presence or absence of coinfection with <em>P. falciparum </em>(<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/7\" class=\"abstract_t\">7</a>]. These manifestations include hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, and seizures [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H600000324\"><span class=\"h2\">By species</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the above manifestations, some clinical syndromes are associated with particular malaria species.</p><p class=\"headingAnchor\" id=\"H760406136\"><span class=\"h3\">P. vivax and P. ovale</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include a hypnozoite liver stage, which is a dormant stage that can reactivate weeks, months, or years after the initial infection, causing relapse [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> below.)</p><p>Infection caused by <em>P. vivax</em> can be mild or severe. Severe manifestations include anemia with hemolysis, disseminated intravascular coagulation, thrombocytopenia, and acute lung injury [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/4,5,51-54\" class=\"abstract_t\">4,5,51-54</a>]. Hemodynamic instability, hepatic failure, renal failure, and coma have also been described [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/26,52\" class=\"abstract_t\">26,52</a>]. Splenic rupture is a rare complication of <em>P. vivax</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/55-57\" class=\"abstract_t\">55-57</a>].</p><p><em>P. vivax</em> exists in tropical and temperate forms. The more prevalent tropical form causes malaria that relapses within three weeks of onset of the primary attack and then at approximately two-month intervals thereafter (unless slowly eliminated antimalarial drugs are given, in which case the relapse interval is five to seven weeks). The majority of relapses in tropical strains occur within six months, but heavily infected patients or patients with prolonged exposure may continue relapsing up to two years and rarely up to four years or more. The temperate form may have an incubation period of up to nine months and a similarly long interval between infection and relapse. The tropical form tends to be less sensitive to <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> than the temperate form. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p>Reports of severe <em>P. ovale</em> malaria are rare; this likely reflects the relative rarity of <em>P. ovale</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/7\" class=\"abstract_t\">7</a>]. Splenic rupture, thrombocytopenia, and disseminated intravascular coagulation have been associated with <em>P. ovale</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/58-61\" class=\"abstract_t\">58-61</a>].</p><p class=\"headingAnchor\" id=\"H511192898\"><span class=\"h3\">P. malariae</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Malaria due to <em>P. malariae</em> typically causes a relatively mild illness with relatively low parasitemia. Low-level asymptomatic infection can persist for months or years and may be associated with anemia [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/5\" class=\"abstract_t\">5</a>]. In addition, <em>P. malariae</em> may be associated with relapse even decades after exposure; the mechanism of persistence is unknown [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/41\" class=\"abstract_t\">41</a>].</p><p>Chronic <em>P. malariae</em> infection in children has been associated with nephrotic syndrome due to a mixed immunoglobulin (Ig)M and IgG basement membrane immune complex nephropathy [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/62-65\" class=\"abstract_t\">62-65</a>]; one study noted the risk of this complication of 1 in 200 children &lt;5 years of age [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/66\" class=\"abstract_t\">66</a>]. Most patients die within two years of this diagnosis, although cure has been described with early recognition and prompt treatment with antimalarial and glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/67-70\" class=\"abstract_t\">67-70</a>].</p><p><em>P. knowlesi</em> may be misdiagnosed as <em>P. malariae</em> microscopically. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-knowlesi#H1623954686\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium knowlesi&quot;, section on 'Diagnosis'</a>.)</p><p>There are some reports of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> failure in patients with infection due to <em>P. malariae</em>; these may reflect inadequate drug absorption rather than drug resistance. (See <a href=\"#H3096494374\" class=\"local\">'Chloroquine resistance'</a> above.)</p><p class=\"headingAnchor\" id=\"H1215777709\"><span class=\"h2\">Relapse</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include hypnozoites, which are dormant stages in the liver that can reactivate and cause relapse weeks, months, or years after the initial infection (<a href=\"image.htm?imageKey=ID%2F70176\" class=\"graphic graphic_figure graphicRef70176 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/14\" class=\"abstract_t\">14</a>]. The presence of hypnozoites in the liver is not associated with clinical symptoms, and, thus far, diagnostic technology cannot detect these latent parasites. Symptoms of relapse occur when reactivated hypnozoites are released into the systemic circulation. Relapse can also occur in the absence of symptomatic primary infection; this has been observed among individuals who have taken malaria prophylaxis during travel in endemic areas [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/71\" class=\"abstract_t\">71</a>].</p><p>The character of relapses vary with geography of transmission [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For malaria strains acquired in tropical areas, the risk of relapse exceeds 80 percent; first relapses typically occur 21 to 30 days of the initial symptomatic illness. Four or more relapses may occur at approximately two-month intervals [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/73\" class=\"abstract_t\">73</a>]. As many as 10 to 20 relapses within two years have been described.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For malaria strains acquired in temperate areas, the risk of relapse is &lt;30 percent; relapses typically occur 6 to 12 months after infection, and typically fewer than three relapses occur in the subsequent months [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/74\" class=\"abstract_t\">74</a>]. In India, <em>P. vivax</em> seems to behave more like temperate than tropical strains [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/75\" class=\"abstract_t\">75</a>].</p><p/><p>Among infants with <em>P. vivax</em> infection, relapse is usually due to a genetically homologous strain; among adults, relapse may result from reactivation of a heterogeneous population of hypnozoites from prior episodes of infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/76\" class=\"abstract_t\">76</a>].</p><p>Relapse due to <em>P. vivax</em> may be triggered by acute febrile illness (including infection caused by <em>P. falciparum</em>, relapsing fever, trench fever, epidemic typhus, and brucellosis) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/16,77\" class=\"abstract_t\">16,77</a>].</p><p>Relapse due to <em>P. ovale</em> is relatively rare. Most reports describe relapse within 17 to 255 days, although one report describes relapse four years following infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/78-80\" class=\"abstract_t\">78-80</a>].</p><p>Relapse may be prevented by administration of presumptive anti-relapse therapy. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Hyperreactive splenomegaly</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hyperreactive malarial splenomegaly (HMS), previously known as tropical splenomegaly syndrome (TSS), is a complication of chronic malaria. The prevalence is high in Eastern Indonesia and Papuan highlands where <em>P. vivax</em> and <em>P. malariae</em> are the predominant species, although it can occur in association with any malaria species [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/81-84\" class=\"abstract_t\">81-84</a>].</p><p>HMS occurs as a result of overproduction of IgM secondary to repeated infection, with subsequent formation of immune complexes that cause prolonged stimulation of splenic reticuloendothelial cells. Among patients in Indonesia with HMS and elevated <em>P. vivax</em> antibody titers, antibody overproduction has been linked to a decrease in T-suppressor lymphocytes that normally downregulate B-lymphocyte function and antibody production [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/85\" class=\"abstract_t\">85</a>].</p><p>Clinical manifestations of HMS include left upper quadrant pain, fatigue, ascites, lower extremity edema, and dyspnea; these symptoms become debilitating as the disease progresses [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/86\" class=\"abstract_t\">86</a>]. Parasitemia is uncommon; the diagnosis is generally made among long-term residents of malarious areas based on presence of massive splenomegaly, high serum antimalarial antibody levels, and polyclonal IgM hypergammaglobulinemia. PCR amplification of plasmodial DNA in the absence of parasitemia can confirm the diagnosis [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/83,85\" class=\"abstract_t\">83,85</a>]. Demonstration of malaria infection correlates with treatment success [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/87\" class=\"abstract_t\">87</a>].</p><p>Management of HMS is discussed below. (See <a href=\"#H3447025753\" class=\"local\">'Hyperreactive splenomegaly'</a> below.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Malaria should be suspected in the setting of febrile illness after exposure to a region where malaria is endemic [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/88,89\" class=\"abstract_t\">88,89</a>]. The diagnosis is established by blood smear microscopy or rapid diagnostic test (RDT). Polymerase chain reaction (PCR) is primarily a research tool.</p><p>Microscopic examination of Giemsa-stained blood smears is the traditional method for diagnosis of malaria. This technique allows determination of parasitemia and the life cycle stages present (<a href=\"image.htm?imageKey=ID%2F80296\" class=\"graphic graphic_figure graphicRef80296 \">figure 2</a> and <a href=\"image.htm?imageKey=ID%2F53291\" class=\"graphic graphic_table graphicRef53291 \">table 1</a>). The limit of detection of microscopy is about 20 <span class=\"nowrap\">parasites/microL</span> in expert hands. It would be unlikely for a patient to present with acute illness and parasitemia below the limit of detection of microscopy. Competent microscopy requires ongoing training and evaluation and proper supplies and equipment.</p><p>RDTs are straightforward to use and interpret and do not require specialized laboratory skills or equipment [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/80\" class=\"abstract_t\">80</a>]. However, RDTs have a limit of detection &gt;100 to 200 <span class=\"nowrap\">parasites/microL</span> and do not allow determination of parasitemia or life cycle stages present; ideally, RDTs should complement standard microscopic examinations of Giemsa-stained blood films if possible. Species reporting depends on the type of RDT and may be limited to <em>P. falciparum</em> only, <em>P. falciparum </em>versus non-falciparum species (not specified), or <em>P. falciparum</em> versus <em>P. vivax</em>. There are no RDTs for definitive diagnosis of <em>P. malariae, P. ovale, </em>or<em> P. knowlesi.</em></p><p>PCR diagnosis typically detects as low as 1 <span class=\"nowrap\">parasite/microL</span>. PCR diagnosis with a negative RDT may be useful where competent malaria microscopy is not available.</p><p><em>P. knowlesi</em> appears morphologically similar to <em>P. malariae</em> by microscopy; molecular diagnostic procedures are required for confirmation of <em>P. knowlesi</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/90\" class=\"abstract_t\">90</a>]. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-knowlesi#H1623954686\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium knowlesi&quot;, section on 'Diagnosis'</a>.)</p><p>Mixed infections represent a diagnostic challenge. Microscopists may miss detection of an additional species, and RDTs are not capable of detecting whether more than one infection is present. In such cases, molecular diagnostics may be needed to definitively exclude falciparum malaria; access to such tools may not be available. (See <a href=\"#H3579616738\" class=\"local\">'Mixed infection'</a> below.)</p><p>Additional evaluation should include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count (evaluating for severe anemia, thrombocytopenia) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/91\" class=\"abstract_t\">91</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver function testing, including fractionated bilirubin (evaluating for hepatitis, hemolysis)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basic metabolic panel (evaluating for renal failure, metabolic acidosis, hypoglycemia)</p><p/><p>Issues related to diagnosis of malaria are discussed further separately. (See <a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H697280631\"><span class=\"h2\">Uncomplicated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncomplicated non-falciparum malaria refers to malaria infection caused by a non-falciparum species in the absence of hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, or seizures [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>].</p><p>If the infecting species is not known with certainty, treatment for uncomplicated <em>P. falciparum</em> should be administered. In addition, patients with mixed infections that include <em>P. falciparum</em> should receive definitive treatment for <em>P. falciparum</em>. (See <a href=\"#H3579616738\" class=\"local\">'Mixed infection'</a> below and <a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Treatment of uncomplicated falciparum malaria in nonpregnant adults and children&quot;</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women\" class=\"medical medical_review\">&quot;Prevention and treatment of malaria in pregnant women&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2909789414\"><span class=\"h3\">Antimalarial selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of non-falciparum malaria consists of treating the erythrocytic forms (<a href=\"image.htm?imageKey=ID%2F70176\" class=\"graphic graphic_figure graphicRef70176 \">figure 1</a> and <a href=\"image.htm?imageKey=ID%2F107988\" class=\"graphic graphic_algorithm graphicRef107988 \">algorithm 1</a>). In addition, treatment of infections caused by <em>P. vivax</em> and <em>P. ovale</em> requires eradication of liver hypnozoites to prevent relapse of infection. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p>Patients with uncomplicated infection due to <em>P. vivax</em>, <em>P. ovale,</em> and <em>P. malariae</em> in the absence of other comorbidities can usually be managed on an outpatient basis. </p><p class=\"headingAnchor\" id=\"H1074782758\"><span class=\"h4\">Chloroquine-sensitive infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of non-falciparum malaria consists of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> or an artemisinin combination therapy (ACT) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>]. In settings where there is no endemic <em>P. falciparum</em> malaria and chloroquine resistance remains low, chloroquine may be used with ongoing monitoring; use of ACT should be implemented when the chloroquine treatment failure rate at day 28 is &gt;10 percent [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>]. Some regions favor a universal policy of treatment with artemisinin combination therapy for all species of malaria [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/92\" class=\"abstract_t\">92</a>].</p><p>Dosing of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> consists of a total dose of 25 mg <span class=\"nowrap\">base/kg</span> administered as 10 mg <span class=\"nowrap\">base/kg</span> orally on day 1, followed by 10 mg <span class=\"nowrap\">base/kg</span> orally on day 2, and 5 mg <span class=\"nowrap\">base/kg</span> on day 3. Minor side effects of chloroquine (including bitter taste, gastrointestinal disturbances, dizziness, blurred vision, and headache) may be alleviated by taking the drug with food. (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a>.)</p><p>Dosing for ACTs is summarized in the Table (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>). ACTs containing piperaquine, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, or lumefantrine are favored; artesunate-amodiaquine may be effective in some areas [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>]. Artesunate-sulfadoxine-pyrimethamine is not an appropriate regimen for treatment of non-falciparum malaria.</p><p>Gametocytes of non-falciparum malaria species are susceptible to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>; no additional therapy is required to target this stage (as is administered to patients with <em>P. falciparum</em> infection in some areas reduce transmissibility of treated infection). (See <a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children#H4118771064\" class=\"medical medical_review\">&quot;Treatment of uncomplicated falciparum malaria in nonpregnant adults and children&quot;, section on 'Reducing transmissibility'</a>.)</p><p><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> is highly effective against erythrocytic forms of <em>P. malariae,</em> <em>P. ovale, </em>and chloroquine-sensitive <em>P. vivax</em> [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/93\" class=\"abstract_t\">93</a>]. A systematic review including 14 trials and more than 2500 participants noted ACTs are at least equivalent to chloroquine at treating the blood stage of <em>P. vivax</em> infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/94\" class=\"abstract_t\">94</a>]. Dihydroartemisinin-piperaquine is the most studied ACT for treatment of non-falciparum malaria; it may provide a longer period of post-treatment prophylaxis than <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a> or artesunate-amodiaquine. Resistance has compromised the efficacy of artesunate-sulfadoxine-pyrimethamine, and this agent is not an appropriate regimen for treatment of non-falciparum malaria [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Other agents with activity against non-falciparum malaria include <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>, <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, or a combination of <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> plus <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (<a href=\"image.htm?imageKey=ID%2F107829\" class=\"graphic graphic_table graphicRef107829 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/95-100\" class=\"abstract_t\">95-100</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h4\">Chloroquine-resistant infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> resistance has been associated with <em>P. vivax</em> infection in certain regions. (See <a href=\"#H3096494374\" class=\"local\">'Chloroquine resistance'</a> above.)</p><p><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> resistance is defined as persistent <em>P. vivax</em> parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy with adequate drug concentrations (defined as &gt;100 <span class=\"nowrap\">ng/mL</span> whole blood concentrations of chloroquine plus its metabolite desethylchloroquine) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/13,19\" class=\"abstract_t\">13,19</a>].</p><p><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> resistance is difficult to diagnose, since recurrent parasitemia may also be caused by relapse or reinfection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/101\" class=\"abstract_t\">101</a>]. (See <a href=\"#H2740129559\" class=\"local\">'Recurrent infection'</a> below.)</p><p>Patients with infection due to isolates with low-grade <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance (eg, in areas with less than 10 percent <em>P. vivax</em> recurrence at day 28) may be treated with chloroquine (plus a two-week course of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> for prevention of relapse) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/45,102\" class=\"abstract_t\">45,102</a>]. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p>The preferred regimen for treatment of chloroquine-resistant non-falciparum malaria consists of artemisinin combination therapy (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/103-108\" class=\"abstract_t\">103-108</a>]. ACTs with relatively rapid elimination of the partner drug (such as <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a>) should be combined with a two-week course of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> to reduce the risk of relapse [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/102\" class=\"abstract_t\">102</a>]. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p>Other agents with activity against chloroquine-resistant non-falciparum malaria include<em> </em><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, or a combination of <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> plus <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (<a href=\"image.htm?imageKey=ID%2F107829\" class=\"graphic graphic_table graphicRef107829 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/109-111\" class=\"abstract_t\">109-111</a>].</p><p class=\"headingAnchor\" id=\"H3579616738\"><span class=\"h4\">Mixed infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with mixed infections that include <em>P. falciparum</em> should receive definitive treatment for <em>P. falciparum</em>. In areas where both <em>P. vivax</em> and <em>P. falciparum</em> are endemic and species diagnosis is not reliable, a regimen with activity against both falciparum and non-falciparum malaria (such as an artemisinin combination therapy) should be administered. (See <a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Treatment of uncomplicated falciparum malaria in nonpregnant adults and children&quot;</a>.)</p><p><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> should also be administered to patients with <em>P. vivax </em>or <em>P. ovale</em> infection to prevent relapse (in the absence of glucose-6-phosphate dehydrogenase [G6PD] deficiency) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1,92\" class=\"abstract_t\">1,92</a>]. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> below.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Preventing relapse</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations of relapse are described above. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> above.)</p><p>Presumptive anti-relapse therapy with <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> is required to eradicate the hypnozoite liver stages of <em>P. vivax</em> and <em>P. ovale</em> in both low- and high-transmission settings<em> </em>(<a href=\"image.htm?imageKey=ID%2F70176\" class=\"graphic graphic_figure graphicRef70176 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1,112,113\" class=\"abstract_t\">1,112,113</a>]. Primaquine should be started after fever has subsided and normal G6PD status has been confirmed. The efficacy of primaquine for prevention of relapse is &gt;90 percent [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/17,114\" class=\"abstract_t\">17,114</a>]. Adherence to primaquine may be diminished after resolution of symptoms; observed treatment may be warranted [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/115-117\" class=\"abstract_t\">115-117</a>]. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> above.)</p><p>At least two commercially available point-of-care G6PD test kits are available, one in the United States (BINAX Now G6PD) and one outside the United States (CareStart G6PD). These tests render a relatively easily read color change for diagnosis within 10 minutes from a finger stick sample of blood.</p><p>Dosing of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> for prevention of relapse caused by malaria strains acquired in tropical areas consists of 0.5 mg <span class=\"nowrap\">base/kg</span> per day for 14 days; primaquine dosing for prevention of relapse caused by malaria strains acquired in temperate areas consists of 0.25 mg <span class=\"nowrap\">base/kg</span> per day for 14 days [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>]. The higher dose may cause some gastrointestinal discomfort in some patients; this can be relieved by splitting the daily dose to twice per day and administering with food. The lower dose may be adequate for eradication of <em>P. ovale</em> hypnozoites.</p><p><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> can cause severe hemolysis in individuals with G6PD deficiency, an X-linked disorder. Therefore, primaquine is contraindicated for patients deficient in G6PD, pregnant women (since the G6PD status of the fetus cannot be determined), infants less than six months of age (since G6PD testing can be confounded by fetal hemoglobin in early life), and women breastfeeding infants less than six months old. (See <a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women#H4\" class=\"medical medical_review\">&quot;Prevention and treatment of malaria in pregnant women&quot;, section on 'Non-falciparum malaria'</a>.)</p><p>Most quantitative tests define G6PD deficiency at enzyme activity below 30 percent. Females who are heterozygous for the trait (enzyme activity between 30 and 80 percent) may be vulnerable to some degree of hemolysis; such patients should be counseled regarding signs and symptoms of hemolytic anemia and advised to stop <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> and seek care should these develop [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/118\" class=\"abstract_t\">118</a>]. For patients with mild G6PD deficiency (&gt;30 percent residual activity), a modified regimen of primaquine (0.75 mg <span class=\"nowrap\">base/kg)</span> once weekly for eight weeks has been suggested, although the data for safety and efficacy of this regimen are limited [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1,119\" class=\"abstract_t\">1,119</a>]. Patients with mutant cytochrome P-450 2D6 are unable to metabolize primaquine and may suffer relapses despite high-dose primaquine therapy [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/120\" class=\"abstract_t\">120</a>]. (See <a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency\" class=\"medical medical_review\">&quot;Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency&quot;</a>.)</p><p>Patients unable to take <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> should be counseled regarding the possibility of developing relapsing infection (ranging from 5 to 80 percent) and be advised to seek treatment if symptoms recur [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/121\" class=\"abstract_t\">121</a>]. Patients with relapsing infection should receive repeat treatment with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>. For patients unable to take primaquine who experience frequent relapse, chloroquine prophylaxis (300 mg base weekly for 12 months) may be administered, although late relapses may still occur [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/95\" class=\"abstract_t\">95</a>]. In the setting of chloroquine-resistant <em>P. vivax</em>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> prophylaxis (228 mg base weekly) may be used.</p><p>Tafenoquine is a long-acting 8-aminoquinoline with hypnozoiticidal activity; as with <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a>, it can cause hemolysis in individuals with G6PD deficiency [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/122,123\" class=\"abstract_t\">122,123</a>]. In a large multicenter randomized controlled trial, administration of tafenoquine (300 mg single dose) was well tolerated and more effective in preventing relapse after <em>P. vivax</em> malaria infection than <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> alone or chloroquine plus primaquine [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/122\" class=\"abstract_t\">122</a>]. Further study is pending.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Monitoring and follow up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With appropriate treatment, fever and parasitemia usually resolve within two to four days; this may vary depending on strain differences, host factors, and type of antimalarial therapy. Serial blood smears should be performed after initiation of treatment. In general, following <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> treatment, the parasite density should be lower than 25 percent of the pretreatment density by day 3 and undetectable by day 4. The speed of the parasite clearance (assessed by microscopy) is a reasonable marker of parasite susceptibility; parasite clearance in 95 percent of patients by day 2 or all patients by day 3 is 100 percent predictive of chloroquine sensitivity [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Clinical manifestations of malaria in nonpregnant adults and children&quot;</a>.)</p><p>Daily smears should be performed until parasitemia is no longer detectable. Repeat testing on days 7 and 28 following initiation of therapy is appropriate to confirm cure, even in the absence of symptoms. Recurrent fever over the next six months may signal recurrent infection and<em> </em>should prompt repeat blood smear.</p><p class=\"headingAnchor\" id=\"H2740129559\"><span class=\"h3\">Recurrent infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent infection can result from recrudescence, relapse, or reinfection; these may be difficult to distinguish:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recrudescence (treatment failure) refers to the reemergence of blood stage forms following reduction of parasitemia and resolution of clinical symptoms yet incomplete clearance of infection; it generally occurs within six to nine weeks after an initial infection [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/124\" class=\"abstract_t\">124</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Relapse refers to reactivation of liver hypnozoites weeks to months after the initial treatment and thus represents failure of hypnozoiticidal treatment (if administered).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reinfection refers to new infection transmitted via mosquito exposure.</p><p/><p>Patients with recurrent infection should be treated promptly with an alternate agent. Options include artemisinin combination therapy, <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, or <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> plus <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> (or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>). Antimalarial selection should be individualized based on local resistance patterns where the infection was acquired.</p><p class=\"headingAnchor\" id=\"H3447025753\"><span class=\"h3\">Hyperreactive splenomegaly</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations of hyperreactive splenomegaly are described above. (See <a href=\"#H13\" class=\"local\">'Hyperreactive splenomegaly'</a> above.)</p><p>Treatment of hyperreactive splenomegaly consists of antimalarial therapy for the duration of ongoing malaria exposure. <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> (300 mg base [= 500 mg salt]) once weekly is effective in reducing spleen size and symptoms over several months in 70 to 80 percent of cases [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/82,86\" class=\"abstract_t\">82,86</a>]. In areas with known chloroquine resistance, alternative agents should be used for initial treatment followed by prophylactic doses. Splenectomy carries an appreciable risk of mortality and so should only be considered as a treatment for severely debilitating massive splenomegaly unresponsive to medical management [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/82,125\" class=\"abstract_t\">82,125</a>].</p><p class=\"headingAnchor\" id=\"H3665948362\"><span class=\"h2\">Severe infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe malaria should be treated for presumed <em>P. falciparum</em> infection, regardless of species diagnosis (<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 2</a>). (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p>Severe non-falciparum malaria refers to malaria infection caused by a non-falciparum species associated with manifestations such as hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, or seizures [<a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H1200357325\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-falciparum malaria refers to malaria infection due to <em>Plasmodium</em> species other than <em>P. falciparum</em>; these include <em>P. vivax</em>, <em>P. ovale</em>, <em>P. malariae</em>, and <em>P. knowlesi </em>(<a href=\"image.htm?imageKey=ID%2F53291\" class=\"graphic graphic_table graphicRef53291 \">table 1</a>).<em> P. vivax</em> is the most important non-falciparum malaria species; approximately one-third of the world's population is at risk for infection caused by this species. Infections caused by<em> P. knowlesi</em> and <em>P. vivax</em> are associated with significant risk of morbidity and mortality; severe disease due to <em>P. malariae</em> and <em>P. ovale</em> is relatively rare. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The incubation period of non-falciparum malaria is 9 to 14 days. Clinical manifestations of uncomplicated malaria include fever, chills, headache, fatigue, malaise, myalgia, and other symptoms. Clinical manifestations of severe malaria include hemodynamic instability, severe anemia, metabolic acidosis, renal failure, altered mental status, and other symptoms. (See <a href=\"#H7\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include hypnozoites, which are dormant stages in the liver that can reactivate weeks, months, or years after the initial infection, causing relapse. (See <a href=\"#H1215777709\" class=\"local\">'Relapse'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malaria should be suspected in the setting of febrile illness after exposure to a region where malaria is endemic. The diagnosis is established by blood smear microscopy or rapid diagnostic test. (See <a href=\"#H15\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of uncomplicated non-falciparum malaria consists of treating the erythrocytic forms (<a href=\"image.htm?imageKey=ID%2F70176\" class=\"graphic graphic_figure graphicRef70176 \">figure 1</a> and <a href=\"image.htm?imageKey=ID%2F107988\" class=\"graphic graphic_algorithm graphicRef107988 \">algorithm 1</a>). If the infecting species is not known with certainty, treatment for uncomplicated <em>P. falciparum</em> should be administered. Patients with mixed infections that include <em>P. falciparum</em> should receive definitive treatment for <em>P. falciparum</em>. Patients with severe malaria should be treated for presumed severe <em>P. falciparum</em> infection, regardless of species diagnosis (<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 2</a>). (See <a href=\"#H2909789414\" class=\"local\">'Antimalarial selection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest treating chloroquine-sensitive non-falciparum malaria with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> or artemisinin combination therapy (ACT) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Dosing for chloroquine is summarized above; dosing for ACTs is summarized in the Table (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>). (See <a href=\"#H1074782758\" class=\"local\">'Chloroquine-sensitive infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> resistance has been associated with <em>P. vivax</em> infection in certain regions; it is defined as persistent <em>P. vivax</em> parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy. We suggest treating chloroquine-resistant non-falciparum malaria with ACT (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>) (<a href=\"image.htm?imageKey=ID%2F107830\" class=\"graphic graphic_table graphicRef107830 \">table 3</a>). (See <a href=\"#H3096494374\" class=\"local\">'Chloroquine resistance'</a> above and <a href=\"#H19\" class=\"local\">'Chloroquine-resistant infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend presumptive anti-relapse therapy to eradicate the hypnozoite liver stages of <em>P. vivax</em> and <em>P. ovale</em> (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> should be started after fever has subsided and normal glucose-6-phosphate dehydrogenase (G6PD) status has been confirmed. Dosing is summarized above. (See <a href=\"#H20\" class=\"local\">'Preventing relapse'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With appropriate treatment, fever and parasitemia usually resolve within two to four days. Daily smears should be performed until parasitemia is no longer detectable. Repeat testing on days 7 and 28 following initiation of therapy is appropriate to confirm cure, even in the absence of symptoms. (See <a href=\"#H21\" class=\"local\">'Monitoring and follow up'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent infection can result from recrudescence, relapse, or reinfection; these may be difficult to distinguish. (See <a href=\"#H2740129559\" class=\"local\">'Recurrent infection'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H5023674\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Jason Maguire, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&amp;ua=1 (Accessed on October 22, 2015).</li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/2\" class=\"nounderline abstract_t\">Millar SB, Cox-Singh J. Human infections with Plasmodium knowlesi--zoonotic malaria. Clin Microbiol Infect 2015; 21:640.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/3\" class=\"nounderline abstract_t\">Seilmaier M, Hartmann W, Beissner M, et al. Severe Plasmodium knowlesi infection with multi-organ failure imported to Germany from Thailand/Myanmar. Malar J 2014; 13:422.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/4\" class=\"nounderline abstract_t\">Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013; 26:36.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/5\" class=\"nounderline abstract_t\">Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med 2013; 10:e1001575; discussion e1001575.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/6\" class=\"nounderline abstract_t\">Tomar LR, Giri S, Bauddh NK, Jhamb R. Complicated malaria: a rare presentation of Plasmodium ovale. Trop Doct 2015; 45:140.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/7\" class=\"nounderline abstract_t\">Hwang J, Cullen KA, Kachur SP, et al. Severe morbidity and mortality risk from malaria in the United States, 1985-2011. Open Forum Infect Dis 2014; 1:ofu034.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/8\" class=\"nounderline abstract_t\">Mace KE, Arguin PM. Malaria Surveillance - United States, 2014. MMWR Surveill Summ 2017; 66:1.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/9\" class=\"nounderline abstract_t\">Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004; 4:327.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/10\" class=\"nounderline abstract_t\">Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6:e1814.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/11\" class=\"nounderline abstract_t\">Broderick C, Nadjm B, Smith V, et al. Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study. BMJ 2015; 350:h1703.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/12\" class=\"nounderline abstract_t\">Robert LL, Santos-Ciminera PD, Andre RG, et al. Plasmodium-infected Anopheles mosquitoes collected in Virginia and Maryland following local transmission of Plasmodium vivax malaria in Loudoun County, Virginia. J Am Mosq Control Assoc 2005; 21:187.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/13\" class=\"nounderline abstract_t\">Andriopoulos P, Economopoulou A, Spanakos G, Assimakopoulos G. A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece--a re-emerging infection in the southern borders of Europe? Int J Infect Dis 2013; 17:e125.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/14\" class=\"nounderline abstract_t\">White NJ, Imwong M. Relapse. Adv Parasitol 2012; 80:113.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/15\" class=\"nounderline abstract_t\">Betuela I, Rosanas-Urgell A, Kiniboro B, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis 2012; 206:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/16\" class=\"nounderline abstract_t\">Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011; 52:612.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/17\" class=\"nounderline abstract_t\">Sutanto I, Tjahjono B, Basri H, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 2013; 57:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/18\" class=\"nounderline abstract_t\">White MT, Karl S, Battle KE, et al. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife 2014; 3.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/19\" class=\"nounderline abstract_t\">Ryan JR, Stoute JA, Amon J, et al. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am J Trop Med Hyg 2006; 75:575.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/20\" class=\"nounderline abstract_t\">Cavasini CE, Mattos LC, Couto AA, et al. Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? Trans R Soc Trop Med Hyg 2007; 101:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/21\" class=\"nounderline abstract_t\">M&eacute;nard D, Barnadas C, Bouchier C, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 2010; 107:5967.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/22\" class=\"nounderline abstract_t\">Mendes C, Dias F, Figueiredo J, et al. Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 2011; 5:e1192.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/23\" class=\"nounderline abstract_t\">Wurtz N, Mint Lekweiry K, Bogreau H, et al. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J 2011; 10:336.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/24\" class=\"nounderline abstract_t\">Culleton R, Ndounga M, Zeyrek FY, et al. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis 2009; 200:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/25\" class=\"nounderline abstract_t\">Bernabeu M, Gomez-Perez GP, Sissoko S, et al. Plasmodium vivax malaria in Mali: a study from three different regions. Malar J 2012; 11:405.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/26\" class=\"nounderline abstract_t\">Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/27\" class=\"nounderline abstract_t\">Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/28\" class=\"nounderline abstract_t\">Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/29\" class=\"nounderline abstract_t\">Nurleila S, Syafruddin D, Elyazar IR, Baird JK. Serious and fatal illness associated with falciparum and vivax malaria among patients admitted to hospital at West Sumba in eastern Indonesia. Am J Trop Med Hyg 2012; 87:41.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/30\" class=\"nounderline abstract_t\">Kochar DK, Das A, Kochar A, et al. A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India. J Vector Borne Dis 2014; 51:200.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/31\" class=\"nounderline abstract_t\">Alexandre MA, Ferreira CO, Siqueira AM, et al. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis 2010; 16:1611.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/32\" class=\"nounderline abstract_t\">Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/33\" class=\"nounderline abstract_t\">McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012; 12:388.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/34\" class=\"nounderline abstract_t\">Maguire JD, Fenton ME, Susanti AI, Walker JB. Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan. Travel Med Infect Dis 2007; 5:301.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/35\" class=\"nounderline abstract_t\">Kotwal RS, Wenzel RB, Sterling RA, et al. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005; 293:212.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/36\" class=\"nounderline abstract_t\">Kawamoto F, Liu Q, Ferreira MU, Tantular IS. How prevalent are Plasmodium ovale and P. malariae in East Asia? Parasitol Today 1999; 15:422.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/37\" class=\"nounderline abstract_t\">Baird JK, Purnomo, Masbar S. Plasmodium ovale in Indonesia. Southeast Asian J Trop Med Public Health 1990; 21:541.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/38\" class=\"nounderline abstract_t\">Sutherland CJ, Tanomsing N, Nolder D, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis 2010; 201:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/39\" class=\"nounderline abstract_t\">Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale--the &quot;bashful&quot; malaria parasites. Trends Parasitol 2007; 23:278.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/40\" class=\"nounderline abstract_t\">Yavne Y, Leshem E, Paran Y, et al. Plasmodium malariae in Israeli Travelers: A Nationwide Study. Clin Infect Dis 2017; 65:1516.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/41\" class=\"nounderline abstract_t\">Morovic M, Poljak I, Miletic B, et al. Late symptomatic Plasmodium malariae relapse in the territory of the former Yugoslavia. J Travel Med 2003; 10:301.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/42\" class=\"nounderline abstract_t\">Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/43\" class=\"nounderline abstract_t\">Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56:621.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/44\" class=\"nounderline abstract_t\">Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/45\" class=\"nounderline abstract_t\">Price RN, von Seidlein L, Valecha N, et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14:982.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/46\" class=\"nounderline abstract_t\">Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/47\" class=\"nounderline abstract_t\">Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007; 101:351.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/48\" class=\"nounderline abstract_t\">Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002; 360:58.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/49\" class=\"nounderline abstract_t\">Betson M, Sousa-Figueiredo JC, Atuhaire A, et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology 2014; 141:1880.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/50\" class=\"nounderline abstract_t\">Grigg MJ, William T, Dhanaraj P, et al. A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial). BMJ Open 2014; 4:e006005.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/51\" class=\"nounderline abstract_t\">Anstey NM, Douglas NM, Poespoprodjo JR, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 2012; 80:151.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/52\" class=\"nounderline abstract_t\">Lampah DA, Yeo TW, Malloy M, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis 2015; 211:623.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/53\" class=\"nounderline abstract_t\">Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of Plasmodium vivax malaria. Malar J 2012; 11:135.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/54\" class=\"nounderline abstract_t\">Barber BE, William T, Grigg MJ, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog 2015; 11:e1004558.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/55\" class=\"nounderline abstract_t\">LUBITZ JM. Pathology of the ruptured spleen in acute vivax malaria. Blood 1949; 4:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/56\" class=\"nounderline abstract_t\">Gockel HR, Heidemann J, Lorenz D, Gockel I. Spontaneous splenic rupture, in tertian malaria. Infection 2006; 34:43.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/57\" class=\"nounderline abstract_t\">Jim&eacute;nez BC, Navarro M, Huerga H, L&oacute;pez-V&eacute;lez R. Spontaneous splenic rupture due to Plasmodium vivax in a traveler: case report and review. J Travel Med 2007; 14:188.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/58\" class=\"nounderline abstract_t\">Facer CA, Rouse D. Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet 1991; 338:896.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/59\" class=\"nounderline abstract_t\">Moudden MK, Boukhira A, Zyani M, et al. [Severe imported malaria: the experience of the Avicenna military hospital of Marrakech]. Sante 2006; 16:259.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/60\" class=\"nounderline abstract_t\">Davis TM, Singh B, Sheridan G. Parasitic procrastination: late-presenting ovale malaria and schistosomiasis. Med J Aust 2001; 175:146.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/61\" class=\"nounderline abstract_t\">Miyashita N, Karino T, Nagatomo Y, et al. [A case of Plasmodium ovale malaria with thrombocytopenia and an abnormality grade in FDP concentration despite the use of chloroquine as a malaria prophylaxis]. Kansenshogaku Zasshi 1995; 69:450.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/62\" class=\"nounderline abstract_t\">GILLES HM, HENDRICKSE RG. Possible aetiological role of Plasmodium malariae in &quot;nephrotic syndrome&quot; in Nigerian children. Lancet 1960; 1:806.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/63\" class=\"nounderline abstract_t\">Abdurrahman MB, Greenwood BM, Narayana P, et al. Immunological aspects of nephrotic syndrome in northern Nigeria. Arch Dis Child 1981; 56:199.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/64\" class=\"nounderline abstract_t\">Abdurrahman MB, Aikhionbare HA, Babaoye FA, et al. Clinicopathological features of childhood nephrotic syndrome in northern Nigeria. Q J Med 1990; 75:563.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/65\" class=\"nounderline abstract_t\">Vinetz JM, Li J, McCutchan TF, Kaslow DC. Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med 1998; 338:367.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/66\" class=\"nounderline abstract_t\">Langford S, Douglas NM, Lampah DA, et al. Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Negl Trop Dis 2015; 9:e0004195.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/67\" class=\"nounderline abstract_t\">Michaud E, Ninet J, Copp&egrave;re B, et al. [Nephrotic syndrome caused by Plasmodium malariae infection. A case with favourable outcome]. Presse Med 1992; 21:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/68\" class=\"nounderline abstract_t\">Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 2006; 98:1977.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/69\" class=\"nounderline abstract_t\">Ehrich JH, Eke FU. Malaria-induced renal damage: facts and myths. Pediatr Nephrol 2007; 22:626.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/70\" class=\"nounderline abstract_t\">Neri S, Pulvirenti D, Patamia I, et al. Acute renal failure in Plasmodium malariae infection. Neth J Med 2008; 66:166.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/71\" class=\"nounderline abstract_t\">Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/72\" class=\"nounderline abstract_t\">Battle KE, Karhunen MS, Bhatt S, et al. Geographical variation in Plasmodium vivax relapse. Malar J 2014; 13:144.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/73\" class=\"nounderline abstract_t\">Ingram RJ, Crenna-Darusallam C, Soebianto S, et al. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 2014; 13:488.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/74\" class=\"nounderline abstract_t\">White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011; 10:297.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/75\" class=\"nounderline abstract_t\">Joshi H, Prajapati SK, Verma A, et al. Plasmodium vivax in India. Trends Parasitol 2008; 24:228.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/76\" class=\"nounderline abstract_t\">Imwong M, Boel ME, Pagornrat W, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis 2012; 205:680.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/77\" class=\"nounderline abstract_t\">Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis 2013; 13:900.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/78\" class=\"nounderline abstract_t\">Chin W, Coatney GR. Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale. Am J Trop Med Hyg 1971; 20:825.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/79\" class=\"nounderline abstract_t\">Chin W, Contacos PG. A recently isolated West African strain of plasmodium ovale. Am J Trop Med Hyg 1966; 15:1.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/80\" class=\"nounderline abstract_t\">TRAGER W, MOST H. A LONG-DELAYED PRIMARY ATTACK OF OVALE MALARIA. Am J Trop Med Hyg 1963; 12:837.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/81\" class=\"nounderline abstract_t\">Hoffman SL, Piessens WF, Ratiwayanto S, et al. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med 1984; 310:337.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/82\" class=\"nounderline abstract_t\">Vriend WH, Hoffman SL, Silaban T, Zaini M. Splenectomy in massive tropical splenomegaly: two-to six-year follow-up in 14 patients. Trop Geogr Med 1988; 40:298.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/83\" class=\"nounderline abstract_t\">Moraes MF, Soares M, Arroz MJ, et al. [New concepts in hyperactive malarial splenomegaly]. Acta Med Port 2003; 16:41.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/84\" class=\"nounderline abstract_t\">Paparello SF, Hoffman SL. Hyperreactive malarial splenomegaly: part I. Postgrad Med 1992; 15:336.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/85\" class=\"nounderline abstract_t\">Mothe B, Lopez-Contreras J, Torres OH, et al. A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests. Infection 2008; 36:167.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/86\" class=\"nounderline abstract_t\">Gupta OP, Bajaj S, Gupta SC. A study on tropical splenomegaly syndrome and chloroquine prophylaxis. J Assoc Physicians India 1989; 37:570.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/87\" class=\"nounderline abstract_t\">McGregor A, Doherty T, Lowe P, et al. Hyperreactive Malarial Splenomegaly Syndrome--Can the Diagnostic Criteria Be Improved? Am J Trop Med Hyg 2015; 93:573.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/88\" class=\"nounderline abstract_t\">Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/89\" class=\"nounderline abstract_t\">Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/90\" class=\"nounderline abstract_t\">Roth JM, Korevaar DA, Leeflang MM, Mens PF. Molecular malaria diagnostics: A systematic review and meta-analysis. Crit Rev Clin Lab Sci 2016; 53:87.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/91\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Morales AJ, S&aacute;nchez E, Vargas M, et al. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr 2006; 52:49.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/92\" class=\"nounderline abstract_t\">Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/93\" class=\"nounderline abstract_t\">Siswantoro H, Russell B, Ratcliff A, et al. In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother 2011; 55:197.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/94\" class=\"nounderline abstract_t\">Gogtay N, Kannan S, Thatte UM, et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 2013; :CD008492.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/95\" class=\"nounderline abstract_t\">Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/96\" class=\"nounderline abstract_t\">Ringwald P, Bickii J, Same-Ekobo A, Basco LK. Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob Agents Chemother 1997; 41:2317.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/97\" class=\"nounderline abstract_t\">Genton B, Baea K, Lorry K, et al. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J 2005; 48:141.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/98\" class=\"nounderline abstract_t\">Borrmann S, Szlez&aacute;k N, Binder RK, et al. Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. J Antimicrob Chemother 2002; 50:751.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/99\" class=\"nounderline abstract_t\">Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 2010; 9:105.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/100\" class=\"nounderline abstract_t\">Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011; 53:977.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/101\" class=\"nounderline abstract_t\">Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 2012; 28:522.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/102\" class=\"nounderline abstract_t\">Abreha T, Hwang J, Thriemer K, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 2017; 14:e1002299.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/103\" class=\"nounderline abstract_t\">Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/104\" class=\"nounderline abstract_t\">Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359:2545.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/105\" class=\"nounderline abstract_t\">Pasaribu AP, Chokejindachai W, Sirivichayakul C, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis 2013; 208:1906.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/106\" class=\"nounderline abstract_t\">Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/107\" class=\"nounderline abstract_t\">Grigg MJ, William T, Menon J, et al. Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clin Infect Dis 2016; 62:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/108\" class=\"nounderline abstract_t\">Siqueira AM, Alencar AC, Melo GC, et al. Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clin Infect Dis 2017; 64:166.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/109\" class=\"nounderline abstract_t\">Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/110\" class=\"nounderline abstract_t\">Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002; 35:e92.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/111\" class=\"nounderline abstract_t\">Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44:1680.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/112\" class=\"nounderline abstract_t\">John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012; 11:280.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/113\" class=\"nounderline abstract_t\">Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 2013; :CD004389.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/114\" class=\"nounderline abstract_t\">Nelwan EJ, Ekawati LL, Tjahjono B, et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med 2015; 13:294.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/115\" class=\"nounderline abstract_t\">Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19:115.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/116\" class=\"nounderline abstract_t\">Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, et al. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health 2011; 42:9.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/117\" class=\"nounderline abstract_t\">Douglas NM, Poespoprodjo JR, Patriani D, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med 2017; 14:e1002379.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/118\" class=\"nounderline abstract_t\">von Seidlein L, Auburn S, Espino F, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 2013; 12:112.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/119\" class=\"nounderline abstract_t\">Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/120\" class=\"nounderline abstract_t\">Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369:1381.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/121\" class=\"nounderline abstract_t\">Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/122\" class=\"nounderline abstract_t\">Rajapakse S, Rodrigo C, Fernando SD. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2015; :CD010458.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/123\" class=\"nounderline abstract_t\">Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/124\" class=\"nounderline abstract_t\">White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18:458.</a></li><li><a href=\"https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae/abstract/125\" class=\"nounderline abstract_t\">Leoni S, Buonfrate D, Angheben A, et al. The hyper-reactive malarial splenomegaly: a systematic review of the literature. Malar J 2015; 14:185.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5706 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H2639591244\" id=\"outline-link-H2639591244\">Non-falciparum malaria species</a><ul><li><a href=\"#H1692802959\" id=\"outline-link-H1692802959\">- Plasmodium vivax</a></li><li><a href=\"#H2392538086\" id=\"outline-link-H2392538086\">- Plasmodium ovale</a></li><li><a href=\"#H938178689\" id=\"outline-link-H938178689\">- Plasmodium malariae</a></li></ul></li><li><a href=\"#H3096494374\" id=\"outline-link-H3096494374\">Chloroquine resistance</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H1913660804\" id=\"outline-link-H1913660804\">Overview</a></li><li><a href=\"#H600000324\" id=\"outline-link-H600000324\">By species</a><ul><li><a href=\"#H760406136\" id=\"outline-link-H760406136\">- P. vivax and P. ovale</a></li><li><a href=\"#H511192898\" id=\"outline-link-H511192898\">- P. malariae</a></li></ul></li><li><a href=\"#H1215777709\" id=\"outline-link-H1215777709\">Relapse</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Hyperreactive splenomegaly</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIAGNOSIS</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">TREATMENT</a><ul><li><a href=\"#H697280631\" id=\"outline-link-H697280631\">Uncomplicated infection</a><ul><li><a href=\"#H2909789414\" id=\"outline-link-H2909789414\">- Antimalarial selection</a><ul><li><a href=\"#H1074782758\" id=\"outline-link-H1074782758\">Chloroquine-sensitive infection</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Chloroquine-resistant infection</a></li><li><a href=\"#H3579616738\" id=\"outline-link-H3579616738\">Mixed infection</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Preventing relapse</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Monitoring and follow up</a></li><li><a href=\"#H2740129559\" id=\"outline-link-H2740129559\">- Recurrent infection</a></li><li><a href=\"#H3447025753\" id=\"outline-link-H3447025753\">- Hyperreactive splenomegaly</a></li></ul></li><li><a href=\"#H3665948362\" id=\"outline-link-H3665948362\">Severe infection</a></li></ul></li><li><a href=\"#H1200357325\" id=\"outline-link-H1200357325\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H5023674\" id=\"outline-link-H5023674\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5706|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ID/107988\" class=\"graphic graphic_algorithm\">- Rx uncomplicated malaria nonfalciparum nonpregnant individuals</a></li></ul></li><li><div id=\"ID/5706|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/70176\" class=\"graphic graphic_figure\">- Plasmodium life cycle</a></li><li><a href=\"image.htm?imageKey=ID/80296\" class=\"graphic graphic_figure\">- Plasmodium blood smears</a></li></ul></li><li><div id=\"ID/5706|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/53291\" class=\"graphic graphic_table\">- Features of malaria species</a></li><li><a href=\"image.htm?imageKey=ID/107439\" class=\"graphic graphic_table\">- Criteria severe falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/107830\" class=\"graphic graphic_table\">- ACTs for rx non-falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/107829\" class=\"graphic graphic_table\">- Alt rx uncomplicated non-falciparum</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">Antimalarial drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Clinical manifestations of malaria in nonpregnant adults and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency\" class=\"medical medical_review\">Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">Diagnosis of malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-knowlesi\" class=\"medical medical_review\">Non-falciparum malaria: Plasmodium knowlesi</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women\" class=\"medical medical_review\">Prevention and treatment of malaria in pregnant women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protection-against-malaria-by-abnormalities-in-red-cell-surface-antigens-and-cytoskeletal-proteins\" class=\"medical medical_review\">Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">Society guideline links: Malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">Treatment of severe malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</a></li></ul></div></div>","javascript":null}